Advanced search
Start date
Betweenand
Related content

ACYL-HYDRAZONE AND OXADIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF

Document type:Patente
Inventor(s): Ricardo José Nunes; Alessandra Mascarello; Rosendo Augusto Yunes; Taisa Regina Stumpf; Paulo Cesar Leal; José Andres Yunes; Carolina Pereira de Souza Melo; Rafael Renatino Canevarolo; Louise Domeneghini Chiaradia; André Bortolini Silveira; Anqelo Brunelli Albertoni Laranjeira
Applicant: Universidade Federal de Santa Catarina (UFSC)
Deposit date: November 2012, 26
INPI register:
EP20120851308 - INPI Search
IPC: C07C251/86 C07D271/107 C07D233/54 C07D333/02 A61K31/166 A61K31/4164 A61K31/381 A61P35/02
Abstract

The present invention relates to acyl-hydrazone compounds, in particular 3,4,5-trimethoxyphenyl-hydrazide derivatives, as well as the oxadiazole analogs thereof and other similar compounds, and to the pharmaceutical use of the same for the treatment of various diseases associated with cell proliferation, such as leukemias, including acute lymphoblastic leukemia (ALL), tumours and inflammation. Acyl-hydrazones have been obtained having activity similar to that of the compound used as a standard in experiments (colchicine). The greater selectivity of the compounds according to the invention is an important feature, associated with fewer side effects than the pharmaceuticals used at present in clinical treatments. The synthetised acyl-hydrazones, more particularly the compounds 02 and 07, exhibited important anti-leukemic activity, which suggests 02 and 07 as candidates to pharmaceutical prototypes, or to pharmaceuticals for the treatment of leukemias, in particular acute lymphoblastic leukemia (ALL), tumours and other proliferative diseases, such as inflammation. The action mechanism of the most active compounds was determined by using DNA microarrays and subsequent tests indicated by the chip, besides selectivity studies in healthy human lymphocytes


FAPESP's process: 09/04167-1 - Metabolomics of methotrexate resistance in acute lymphoblastic leukemia
Grantee:Rafael Renatino Canevarolo
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support type: Scholarships in Brazil - Master

FAPESP's process: 12/11952-0 - Methotrexate resistance is directly associated with glutathione concentration in acute lymphoblastic leukemia cell lines
Grantee:Rafael Renatino Canevarolo
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support type: Scholarships in Brazil - Doctorate

FAPESP's process: 08/02106-2 - IGFBP7 role in chemotherapy resistance of Pediatric Acute Lymphoblastic Leukemia
Grantee:Angelo Brunelli Albertoni Laranjeira
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support type: Scholarships in Brazil - Doctorate

FAPESP's process: 12/03039-2 - IGFBP7 and insulin/IGFs in Childhood Acute Lymphoblastic Leukemia chemoresistance
Grantee:Angelo Brunelli Albertoni Laranjeira
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support type: Scholarships in Brazil - Post-Doctorate

FAPESP's process: 14/08247-8 - Preclinical studies of novel inhibitors of DNA methyltransferase in acute leukemia
Grantee:Nathalia Moreno Cury
Principal Investigator:José Andrés Yunes
Institution: Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB)
Support type: Scholarships in Brazil - Doctorate